nmsg

Nerviano Medical Sciences to present data on novel anticancer molecules at the AACR Annual Meeting 2013

Nerviano, Mar 6, 2013 – Nerviano Medical Sciences will disclose data on novel anticancer molecules at the AACR Annual Meeting 2013.

The presentations include:

Ardini, E et al: “Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models”. Abstract Number: 2091 Presentation Time: Monday, Apr 08, 2012, 1:00 PM - 5:00 PM

Ardini, E et al: “The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models”. Abstract Number: 2092 Presentation Time: Monday, Apr 08, 2012, 1:00 PM - 5:00 PM

Colombo, R et al: “Targeting aneuploidy with NMS-P153, a tight binder inhibitor of the spindle assembly checkpoint MPS1 (TTK) kinase”. Abstract Number: 2097. Presentation Time: Monday, Apr 08, 2012, 1:00 PM - 5:00 PM

Montagnoli, A et al: “Novel isoquinolinone derivatives with dual PARP-1/PARP-3 inhibitory activity are highly active against pTEN mutated colorectal cancer and glioblastoma models”. Abstract Number: 3259. Presentation Time: Tuesday, Apr 09, 2012, 8:00 AM -12:00 PM

Further contributions achieved in collaborative work will be presented by partners (Abstract Number: 4634, “Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin’s lymphoma are effective in cell lines resistant to auristatin based ADCs”; Abstract Number: 4416 “A reporter mouse to measure drug myelotoxicity in time”).

 
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.